Plus   Neg

Soligenix Inc. (SNGX) Is Surging After Orphan Drug Designation

Soligenix Inc. (SNGX) announced Thursday morning that it has been granted an orphan drug designation for RiVax from the European Commission. RiVax is a drug for the prevention of ricin poisoning.

Soligenix gapped up slightly Thursday and has spiked higher in early trade. The stock is now up 0.93 at $2.93 on above average volume. Soligenix has surged to an 8-month high.

For comments and feedback contact: editorial@rttnews.com

Business News

$5 And Under

0 Articles
Follow RTT